GIPSS

genetically inspired prognostic scoring system for primary myelofibrosis

Ayalew Tefferi, Paola Guglielmelli, Maura Nicolosi, Francesco Mannelli, Mythri Mudireddy, Niccolo Bartalucci, Christy M. Finke, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling, Kebede Begna, Gangat Naseema Gangat, Animesh D Pardanani, Alessandro M. Vannucchi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Abstract: International collaborations over the years have produced a series of prognostic models for primary myelofibrosis (PMF), including the recently unveiled mutation-enhanced international prognostic scoring systems for transplant-age patients (MIPSS70 and MIPSS70-plus). In the current study, we considered the feasibility of a genetically inspired prognostic scoring system (GIPSS) that is exclusively based on genetic markers. Among 641 cytogenetically annotated patients with PMF and informative for previously recognized adverse mutations, multivariable analysis identified “VHR” karyotype, “unfavorable” karyotype, absence of type 1/like CALR mutation and presence of ASXL1, SRSF2, or U2AF1Q157 mutation, as inter-independent predictors of inferior survival; the respective HRs (95% CI) were 3.1 (2.1–4.3), 2.1 (1.6–2.7), 2.1 (1.6–2.9), 1.8 (1.5–2.3), 2.4 (1.9–3.2), and 2.4 (1.7–3.3). Based on HR-weighted risk points, a four-tiered GIPSS model was devised: low (zero points; n = 58), intermediate-1 (1 point; n = 260), intermediate-2 (2 points; n = 192), and high (≥3 points; n = 131); the respective median (5-year) survivals were 26.4 (94%), 8.0 (73%), 4.2 (40%), and 2 (14%) years; the model was internally validated by bootstrapping and its predictive accuracy was shown to be comparable to that of MIPSS70-plus. GIPPS offers a low-complexity prognostic tool for PMF that is solely dependent on genetic risk factors and, thus, forward-looking in its essence.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalLeukemia
DOIs
StateAccepted/In press - Mar 23 2018

Fingerprint

Primary Myelofibrosis
Mutation
Karyotype
Survival
Genetic Markers
Transplants

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Tefferi, A., Guglielmelli, P., Nicolosi, M., Mannelli, F., Mudireddy, M., Bartalucci, N., ... Vannucchi, A. M. (Accepted/In press). GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia, 1-12. https://doi.org/10.1038/s41375-018-0107-z

GIPSS : genetically inspired prognostic scoring system for primary myelofibrosis. / Tefferi, Ayalew; Guglielmelli, Paola; Nicolosi, Maura; Mannelli, Francesco; Mudireddy, Mythri; Bartalucci, Niccolo; Finke, Christy M.; Lasho, Terra L.; Hanson, Curtis A.; Ketterling, Rhett P.; Begna, Kebede; Naseema Gangat, Gangat; Pardanani, Animesh D; Vannucchi, Alessandro M.

In: Leukemia, 23.03.2018, p. 1-12.

Research output: Contribution to journalArticle

Tefferi, A, Guglielmelli, P, Nicolosi, M, Mannelli, F, Mudireddy, M, Bartalucci, N, Finke, CM, Lasho, TL, Hanson, CA, Ketterling, RP, Begna, K, Naseema Gangat, G, Pardanani, AD & Vannucchi, AM 2018, 'GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis', Leukemia, pp. 1-12. https://doi.org/10.1038/s41375-018-0107-z
Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018 Mar 23;1-12. https://doi.org/10.1038/s41375-018-0107-z
Tefferi, Ayalew ; Guglielmelli, Paola ; Nicolosi, Maura ; Mannelli, Francesco ; Mudireddy, Mythri ; Bartalucci, Niccolo ; Finke, Christy M. ; Lasho, Terra L. ; Hanson, Curtis A. ; Ketterling, Rhett P. ; Begna, Kebede ; Naseema Gangat, Gangat ; Pardanani, Animesh D ; Vannucchi, Alessandro M. / GIPSS : genetically inspired prognostic scoring system for primary myelofibrosis. In: Leukemia. 2018 ; pp. 1-12.
@article{8054b37c3746463ba83c8ba8bf14aa8c,
title = "GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis",
abstract = "Abstract: International collaborations over the years have produced a series of prognostic models for primary myelofibrosis (PMF), including the recently unveiled mutation-enhanced international prognostic scoring systems for transplant-age patients (MIPSS70 and MIPSS70-plus). In the current study, we considered the feasibility of a genetically inspired prognostic scoring system (GIPSS) that is exclusively based on genetic markers. Among 641 cytogenetically annotated patients with PMF and informative for previously recognized adverse mutations, multivariable analysis identified “VHR” karyotype, “unfavorable” karyotype, absence of type 1/like CALR mutation and presence of ASXL1, SRSF2, or U2AF1Q157 mutation, as inter-independent predictors of inferior survival; the respective HRs (95{\%} CI) were 3.1 (2.1–4.3), 2.1 (1.6–2.7), 2.1 (1.6–2.9), 1.8 (1.5–2.3), 2.4 (1.9–3.2), and 2.4 (1.7–3.3). Based on HR-weighted risk points, a four-tiered GIPSS model was devised: low (zero points; n = 58), intermediate-1 (1 point; n = 260), intermediate-2 (2 points; n = 192), and high (≥3 points; n = 131); the respective median (5-year) survivals were 26.4 (94{\%}), 8.0 (73{\%}), 4.2 (40{\%}), and 2 (14{\%}) years; the model was internally validated by bootstrapping and its predictive accuracy was shown to be comparable to that of MIPSS70-plus. GIPPS offers a low-complexity prognostic tool for PMF that is solely dependent on genetic risk factors and, thus, forward-looking in its essence.",
author = "Ayalew Tefferi and Paola Guglielmelli and Maura Nicolosi and Francesco Mannelli and Mythri Mudireddy and Niccolo Bartalucci and Finke, {Christy M.} and Lasho, {Terra L.} and Hanson, {Curtis A.} and Ketterling, {Rhett P.} and Kebede Begna and {Naseema Gangat}, Gangat and Pardanani, {Animesh D} and Vannucchi, {Alessandro M.}",
year = "2018",
month = "3",
day = "23",
doi = "10.1038/s41375-018-0107-z",
language = "English (US)",
pages = "1--12",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - GIPSS

T2 - genetically inspired prognostic scoring system for primary myelofibrosis

AU - Tefferi, Ayalew

AU - Guglielmelli, Paola

AU - Nicolosi, Maura

AU - Mannelli, Francesco

AU - Mudireddy, Mythri

AU - Bartalucci, Niccolo

AU - Finke, Christy M.

AU - Lasho, Terra L.

AU - Hanson, Curtis A.

AU - Ketterling, Rhett P.

AU - Begna, Kebede

AU - Naseema Gangat, Gangat

AU - Pardanani, Animesh D

AU - Vannucchi, Alessandro M.

PY - 2018/3/23

Y1 - 2018/3/23

N2 - Abstract: International collaborations over the years have produced a series of prognostic models for primary myelofibrosis (PMF), including the recently unveiled mutation-enhanced international prognostic scoring systems for transplant-age patients (MIPSS70 and MIPSS70-plus). In the current study, we considered the feasibility of a genetically inspired prognostic scoring system (GIPSS) that is exclusively based on genetic markers. Among 641 cytogenetically annotated patients with PMF and informative for previously recognized adverse mutations, multivariable analysis identified “VHR” karyotype, “unfavorable” karyotype, absence of type 1/like CALR mutation and presence of ASXL1, SRSF2, or U2AF1Q157 mutation, as inter-independent predictors of inferior survival; the respective HRs (95% CI) were 3.1 (2.1–4.3), 2.1 (1.6–2.7), 2.1 (1.6–2.9), 1.8 (1.5–2.3), 2.4 (1.9–3.2), and 2.4 (1.7–3.3). Based on HR-weighted risk points, a four-tiered GIPSS model was devised: low (zero points; n = 58), intermediate-1 (1 point; n = 260), intermediate-2 (2 points; n = 192), and high (≥3 points; n = 131); the respective median (5-year) survivals were 26.4 (94%), 8.0 (73%), 4.2 (40%), and 2 (14%) years; the model was internally validated by bootstrapping and its predictive accuracy was shown to be comparable to that of MIPSS70-plus. GIPPS offers a low-complexity prognostic tool for PMF that is solely dependent on genetic risk factors and, thus, forward-looking in its essence.

AB - Abstract: International collaborations over the years have produced a series of prognostic models for primary myelofibrosis (PMF), including the recently unveiled mutation-enhanced international prognostic scoring systems for transplant-age patients (MIPSS70 and MIPSS70-plus). In the current study, we considered the feasibility of a genetically inspired prognostic scoring system (GIPSS) that is exclusively based on genetic markers. Among 641 cytogenetically annotated patients with PMF and informative for previously recognized adverse mutations, multivariable analysis identified “VHR” karyotype, “unfavorable” karyotype, absence of type 1/like CALR mutation and presence of ASXL1, SRSF2, or U2AF1Q157 mutation, as inter-independent predictors of inferior survival; the respective HRs (95% CI) were 3.1 (2.1–4.3), 2.1 (1.6–2.7), 2.1 (1.6–2.9), 1.8 (1.5–2.3), 2.4 (1.9–3.2), and 2.4 (1.7–3.3). Based on HR-weighted risk points, a four-tiered GIPSS model was devised: low (zero points; n = 58), intermediate-1 (1 point; n = 260), intermediate-2 (2 points; n = 192), and high (≥3 points; n = 131); the respective median (5-year) survivals were 26.4 (94%), 8.0 (73%), 4.2 (40%), and 2 (14%) years; the model was internally validated by bootstrapping and its predictive accuracy was shown to be comparable to that of MIPSS70-plus. GIPPS offers a low-complexity prognostic tool for PMF that is solely dependent on genetic risk factors and, thus, forward-looking in its essence.

UR - http://www.scopus.com/inward/record.url?scp=85045290065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045290065&partnerID=8YFLogxK

U2 - 10.1038/s41375-018-0107-z

DO - 10.1038/s41375-018-0107-z

M3 - Article

SP - 1

EP - 12

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -